Since selectins are involved in the pathogenesis of most inflammatory diseases/ complications there is a broad spectrum of therapeutic areas as options for developing selectin antagonists, e.g.:

• Transplantation (preclinical data available; (Langer et al., J Am Soc Nephrol. 2004)


• Surgery induced acute kidney injury ( various preclinical data regarding ischemia-reperfusion injury; Calvey et al., J Invest Surg. 2007)


• Psoriasis (preclinical and clinical data; (Friedrich et al., Arch Dermatol Res. 2006)